STOCK TITAN

Journey Medical Corporation - $DERM STOCK NEWS

Welcome to our dedicated page for Journey Medical Corporation news (Ticker: $DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Journey Medical Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Journey Medical Corporation's position in the market.

Rhea-AI Summary

Journey Medical , a pharmaceutical company specializing in dermatological products, will announce its first quarter 2024 financial results on May 13, 2024. The company will host a conference call to discuss the results and provide a corporate update at 4:30 p.m. ET on the same day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.1%
Tags
-
Rhea-AI Summary

Journey Medical has appointed Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Benesch brings over 25 years of experience in financial leadership and reporting, with a focus on the pharmaceutical industry. The company's Co-Founder, President, and CEO praised Benesch's expertise and contributions to the finance and accounting team, emphasizing his role in upcoming milestones like the potential approval of DFD-29 for rosacea treatment. Benesch's extensive background includes positions at Teligent Pharma Inc., Torrent Pharmaceuticals, Savient Pharmaceuticals, Adare Pharmaceuticals, and Edenbridge Pharmaceuticals, along with experience at Baker Tilly Virchow Krause, LLP, and Ernst and Young. With a BA in accounting and CPA certification from Wilkes University, Benesch aims to drive sustainable value for Journey Medical and its shareholders while supporting patients with dermatological products.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.42%
Tags
management
-
Rhea-AI Summary
Journey Medical , a pharmaceutical company focusing on dermatological products, will present at the Planet MicroCap Showcase: Vegas 2024. The Co-Founder and CEO will provide a corporate overview at the conference held on April 30 - May 2, 2024, in Las Vegas.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
conferences
Rhea-AI Summary
Journey Medical (DERM) reports total revenues of $79.2 million for 2023, a 7% increase from 2022. Operating cost savings of $15.6 million exceeded guidance. New Drug Application for rosacea treatment candidate DFD-29 accepted by FDA with a PDUFA goal date of November 4, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.61%
Tags
-
Rhea-AI Summary
Journey Medical (DERM) announces FDA acceptance of NDA for DFD-29 for rosacea treatment with a PDUFA goal date of November 4, 2024. Positive Phase 3 trial data supports the efficacy and safety of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10%
Tags
-
Rhea-AI Summary
Journey Medical (DERM) to host conference call to discuss financial results and provide corporate update on March 21, 2024. The company focuses on selling FDA-approved prescription pharmaceutical products for dermatological conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
Rhea-AI Summary
Journey Medical Corporation (DERM) will participate in the 36th Annual ROTH Conference, with the President and CEO engaging in a fireside chat and one-on-one meetings. A webcast of the chat will be accessible on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
-
Rhea-AI Summary
Journey Medical Corporation (DERM) presents positive Phase 1 clinical trial results for DFD-29 at AAD Annual Meeting. The trial showed no significant safety issues and demonstrated the potential for DFD-29 to treat rosacea effectively. The New Drug Application for DFD-29 is under review by the U.S. FDA.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
-
Rhea-AI Summary
Journey Medical Corporation (DERM) submits NDA for DFD-29, a potential best-in-class oral medication for rosacea treatment, supported by positive Phase 3 clinical data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
none
Rhea-AI Summary
Journey Medical Corporation (Nasdaq: DERM) announced a credit facility with SWK Holdings Corporation for up to $20 million to support general corporate purposes and potential launch of DFD-29.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.29%
Tags
none
Journey Medical Corporation

Nasdaq:DERM

DERM Rankings

DERM Stock Data

68.71M
8.25M
29.91%
9.72%
0.74%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
SCOTTSDALE